Innovative treatment for extrapulmonary benefits in COPD: effects and mechanisms of supramaximal High-Intensity Training
COPD-HIT aims to explore and enhance extrapulmonary treatments for COPD through high-intensity training, focusing on brain health, muscle quality, and cardiac function via innovative research methods.
Projectdetails
Introduction
Given the substantial negative impact of extrapulmonary manifestations on vital clinical outcomes, including mortality, the need for new effective treatment modalities beyond the lungs has been highlighted as an urgent challenge in the management of chronic obstructive pulmonary disease (COPD), one of the most common and deadliest diseases of the 21st century.
Project Aim
The aim of COPD-HIT is to pave the way for new understanding of the development and treatment of extrapulmonary manifestations in COPD with a focus on brain health, muscle quality, and cardiac function.
Research Objectives
To do this, I will focus on the following research objectives (RO):
- RO1: Determine the effect of supramaximal High-Intensity Training (HIT) on the brain, muscle, and heart.
- RO2: Determine how exercise training and inflammation impact the trajectories of neurodegeneration.
- RO3: Develop a novel in-vitro model to determine signaling pathways following various loading intensities.
Methodology
To reach these objectives, I aim to conduct high-quality multicenter randomized controlled and experimental trials.
Further, I will lead an international research alliance with access to state-of-the-art research infrastructures and enable a unique interdisciplinary approach to fulfill my goals. This includes:
- Using advanced measurement techniques for muscle, brain, and cardiorespiratory evaluations.
- Conducting muscle biopsy analyses.
- Implementing in-vivo & in-vitro strategies.
- Combining quantitative and qualitative methods.
Conclusion
Taken together, with COPD-HIT, I am in a strong position to perform an international novel project that will determine how to enable extrapulmonary benefits in COPD in a hitherto unprecedented way.
Financiële details & Tijdlijn
Financiële details
Subsidiebedrag | € 1.490.438 |
Totale projectbegroting | € 1.490.438 |
Tijdlijn
Startdatum | 1-7-2023 |
Einddatum | 30-6-2028 |
Subsidiejaar | 2023 |
Partners & Locaties
Projectpartners
- UMEA UNIVERSITETpenvoerder
Land(en)
Vergelijkbare projecten binnen European Research Council
Project | Regeling | Bedrag | Jaar | Actie |
---|---|---|---|---|
Regulation of the L-arginine – ADMA – Nitric Oxide (NO) Pathway in the Pulmonary Vascular Response to Hypoxia and its Role for Survival of High-Risk COPD PatientsNO PRESSURE aims to uncover the role of intermittent hypoxaemia in COPD progression and identify high-risk patients through innovative molecular and clinical studies targeting the L-arginine-ADMA-NO pathway. | ERC Advanced... | € 2.499.927 | 2023 | Details |
Understanding the host-environmental interactions across the lifespan determining lung function trajectories and COPDPredictCOPD aims to identify early-life gene-environment interactions that influence lung health trajectories, with the goal of preventing COPD and associated multimorbidity through targeted interventions. | ERC Consolid... | € 1.998.319 | 2022 | Details |
Dynamic engIneered heart tiSsue to Study intEr-individual susCeptibily and improve Treatment of Heart FailureDISSECT-HF aims to engineer heart tissue from patient-specific stem cells to uncover common mechanisms of heart failure across different etiologies and improve treatment strategies. | ERC Consolid... | € 1.998.775 | 2022 | Details |
The Mitochondrial Paradox: Embracing Mitohormesis for Improved Metabolic and Aging HealthThis project aims to explore endothelial mitohormesis as a novel therapeutic approach to combat obesity and aging-related disorders using a specialized mouse model. | ERC Proof of... | € 150.000 | 2024 | Details |
Mending sex differences: Unravelling the female predominance in pulmonary hypertensionThis project aims to uncover the mechanisms behind the female predominance in pulmonary hypertension to identify new therapeutic targets and develop selective drug delivery methods for improved treatment. | ERC Starting... | € 1.499.999 | 2023 | Details |
Regulation of the L-arginine – ADMA – Nitric Oxide (NO) Pathway in the Pulmonary Vascular Response to Hypoxia and its Role for Survival of High-Risk COPD Patients
NO PRESSURE aims to uncover the role of intermittent hypoxaemia in COPD progression and identify high-risk patients through innovative molecular and clinical studies targeting the L-arginine-ADMA-NO pathway.
Understanding the host-environmental interactions across the lifespan determining lung function trajectories and COPD
PredictCOPD aims to identify early-life gene-environment interactions that influence lung health trajectories, with the goal of preventing COPD and associated multimorbidity through targeted interventions.
Dynamic engIneered heart tiSsue to Study intEr-individual susCeptibily and improve Treatment of Heart Failure
DISSECT-HF aims to engineer heart tissue from patient-specific stem cells to uncover common mechanisms of heart failure across different etiologies and improve treatment strategies.
The Mitochondrial Paradox: Embracing Mitohormesis for Improved Metabolic and Aging Health
This project aims to explore endothelial mitohormesis as a novel therapeutic approach to combat obesity and aging-related disorders using a specialized mouse model.
Mending sex differences: Unravelling the female predominance in pulmonary hypertension
This project aims to uncover the mechanisms behind the female predominance in pulmonary hypertension to identify new therapeutic targets and develop selective drug delivery methods for improved treatment.
Vergelijkbare projecten uit andere regelingen
Project | Regeling | Bedrag | Jaar | Actie |
---|---|---|---|---|
I-HIT: INTELLIGENT HOLOGAIT INTERVENTION TOOLKITDe I-HIT toolkit ontwikkelt een innovatieve, data-gedreven oplossing met sensortechnologie en Mixed Reality om revalidatie van de onderste extremiteit te verbeteren en versnellen. | Mkb-innovati... | € 206.266 | 2022 | Details |
Comprehensive Analysis of RBM20-induced Dilated Cardiomyopathies using Omics Approaches and Repair InterventionsCARDIOREPAIR aims to identify and therapeutically target RBM20 mutations in dilated cardiomyopathy using high-throughput genomics and bioengineering to improve heart health outcomes. | EIC Pathfinder | € 4.349.410 | 2023 | Details |
High Throughput Cell contractility system for rapid drug evaluationCytocypher en Optics11 ontwikkelen samen een prototype van een high throughput screening systeem voor het functioneel meten van hartspiercellen, ter bevordering van cardiologisch onderzoek. | Mkb-innovati... | € 193.900 | 2015 | Details |
I-HIT: INTELLIGENT HOLOGAIT INTERVENTION TOOLKIT
De I-HIT toolkit ontwikkelt een innovatieve, data-gedreven oplossing met sensortechnologie en Mixed Reality om revalidatie van de onderste extremiteit te verbeteren en versnellen.
Comprehensive Analysis of RBM20-induced Dilated Cardiomyopathies using Omics Approaches and Repair Interventions
CARDIOREPAIR aims to identify and therapeutically target RBM20 mutations in dilated cardiomyopathy using high-throughput genomics and bioengineering to improve heart health outcomes.
High Throughput Cell contractility system for rapid drug evaluation
Cytocypher en Optics11 ontwikkelen samen een prototype van een high throughput screening systeem voor het functioneel meten van hartspiercellen, ter bevordering van cardiologisch onderzoek.